The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

CA913187393

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 5e6ad559-c512-4405-946a-5a91b953e1f9
Approved on: 2020-04-20
Published on: 2020-05-28

HGVS expressions

NM_001079804.3:c.2161del
NC_000017.11:g.80113338del
CM000679.2:g.80113338del
NC_000017.10:g.78087137del
CM000679.1:g.78087137del
NC_000017.9:g.75701732del
NG_009822.1:g.16783del
NM_000152.3:c.2161del
NM_001079803.1:c.2161del
NM_001079804.1:c.2161del
NM_000152.4:c.2161del
NM_001079803.2:c.2161del
NM_001079804.2:c.2161del
NM_000152.5:c.2161del
NM_001079803.3:c.2161del
ENST00000302262.7:c.2161del
ENST00000390015.7:c.2161del
ENST00000572080.1:n.580del

Pathogenic

Met criteria codes 3
PVS1 PM2 PP4_Moderate
Not Met criteria codes 1
PM3

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
This variant, c.2161del (p.Glu721ArgfsTer?), is a frameshift variant predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product. Therefore, PVS1 can be applied. The variant is absent in gnomAD v2.1.1, meeting PM2. This variant was identified by a clinical diagnostic laboratory in a compound heterozygous individual with c.841C>T (p.Arg281Trp). Pseudodeficiency variants are absent in this individual, allowing PP4_Moderate to be applied. The in trans data from this patient was used in the classification of p.Arg281Trp and is not included here in order to avoid a circular argument. An additional case has been reported with p.Glu721ArgfsTer (cDNA sequence not provided), identified by newborn screening and compound heterozygous for p.Trp746Leu and the psuedodeficiency variant p.Asp91Asn (PMIDs 28196920, 29095812). There is no ClinVar entry for this variant and, to our knowledge, functional studies are unavailable. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PP4_Moderate.
Met criteria codes
PVS1
This variant, c.2161delG, is predicted to cause a frameshift, resulting in a premature termination codon, nonsense mediated decay, and lack of gene product. Therefore, PVS1 can be applied.
PM2
This variant is not in gnomAD v2.1.1.
PP4_Moderate
This variant was identified in a compound heterozygote in a clinical diagnostic testing lab. The GAA activity in the patient was in the affected range in a clinically validated dried blood spot assay. Pseudodeficiency variants are absent. Therefore, PP4_Moderate is met.
Not Met criteria codes
PM3
This variant was found in compound heterozygosity in a patient with with c.841C>T (p.Arg281Trp), identified in a clinical diagnostic laboratory. Data from this patient was used in the classification of p.Arg281Trp and is not included here in order to avoid a circular argument.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.